China brain computer interface outfit accelerates to human trials in quest to outpace Neuralink — mix of government backing and investor enthusiasm speeds time to market for NeuroXess

NeuroXess, a Chinese brain computer interface (BCI) company, is advancing quickly towards human trials with a combination of government support and investor interest, potentially positioning China to lead in BCI technology. Founded in 2021, NeuroXess has already conducted successful human BCI trials, showcasing rapid progress. The company's BCI technology allows paralyzed patients to control a computer cursor shortly after implantation without penetrating brain tissue, unlike Neuralink's approach. While NeuroXess's performance metrics slightly lag behind Neuralink's, the company's focus on medical needs and invasive BCI technology could pave the way for advancements in non-invasive systems.